Dracen Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$19.3M
- Investors
-
4
Dracen Pharmaceuticals General Information
Description
Developer of glutamine antagonists designed to treat advanced solid tumors. The company's technology leverages immuno-metabolism and tumor-directed delivery to inhibit glutamine metabolism, providing a treatment paradigm that remodels the tumor microenvironment and stimulates immune responses to shrink tumors and extend patient survival.
Contact Information
Website
www.dracenpharma.comCorporate Office
- 9276 Scranton Road
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 9276 Scranton Road
- Suite 200
- San Diego, CA 92121
- United States
Dracen Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A1) | 10-Aug-2023 | $19.3M | Completed | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC (Series A) | 22-Mar-2018 | Completed | Clinical Trials - Phase 1 | |||
| 1. Accelerator/Incubator | Completed | Startup |
Dracen Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Dracen Pharmaceuticals Patents
Dracen Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024006742-A2 | Nrf2 protein degraders | Inactive | 27-Jun-2022 | ||
| WO-2024006742-A3 | Nrf2 protein degraders | Inactive | 27-Jun-2022 | ||
| WO-2022261117-A1 | Combination therapy with a don prodrug and a tigit inhibitor | Inactive | 07-Jun-2021 | ||
| EP-4221842-A1 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof | Pending | 02-Oct-2020 | ||
| EP-4221842-A4 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof | Pending | 02-Oct-2020 | A61K31/404 |
Dracen Pharmaceuticals Signals
Dracen Pharmaceuticals Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Deerfield Management | Venture Capital | Minority | ||
| i&i Biotech Fund | Venture Capital | Minority | ||
| i&i Prague | Accelerator/Incubator | Minority | ||
| Johns Hopkins Technology Ventures | Accelerator/Incubator | Minority |
Dracen Pharmaceuticals FAQs
-
When was Dracen Pharmaceuticals founded?
Dracen Pharmaceuticals was founded in 2016.
-
Where is Dracen Pharmaceuticals headquartered?
Dracen Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of Dracen Pharmaceuticals?
Dracen Pharmaceuticals has 4 total employees.
-
What industry is Dracen Pharmaceuticals in?
Dracen Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Dracen Pharmaceuticals a private or public company?
Dracen Pharmaceuticals is a Private company.
-
What is the current valuation of Dracen Pharmaceuticals?
The current valuation of Dracen Pharmaceuticals is .
-
What is Dracen Pharmaceuticals’s current revenue?
The current revenue for Dracen Pharmaceuticals is .
-
How much funding has Dracen Pharmaceuticals raised over time?
Dracen Pharmaceuticals has raised $59.3M.
-
Who are Dracen Pharmaceuticals’s investors?
Deerfield Management, i&i Biotech Fund, i&i Prague, and Johns Hopkins Technology Ventures have invested in Dracen Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process